(Q33378811)

English

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid (English)

1 reference

Europe PubMed Central

26 July 2017

0 references

Frédérique Penault-Llorca

8

object named as

Frederique Penault-Llorca

0 references

10

object named as

Manfred Dietel

1 reference

Europe PubMed Central

26 July 2017

author name string

Hiroaki Nitta

1

1 reference

Europe PubMed Central

26 July 2017

Beatrice Hauss-Wegrzyniak

2

1 reference

Europe PubMed Central

26 July 2017

Megan Lehrkamp

3

1 reference

Europe PubMed Central

26 July 2017

Adrian E Murillo

4

1 reference

Europe PubMed Central

26 July 2017

Fabien Gaire

5

1 reference

Europe PubMed Central

26 July 2017

Michael Farrell

6

1 reference

Europe PubMed Central

26 July 2017

Eric Walk

7

1 reference

Europe PubMed Central

26 July 2017

Frederique Penault-Llorca

8

1 reference

Europe PubMed Central

26 July 2017

Masafumi Kurosumi

9

1 reference

Europe PubMed Central

26 July 2017

Lin Wang

11

1 reference

Europe PubMed Central

26 July 2017

Margaret Loftus

12

1 reference

Europe PubMed Central

26 July 2017

James Pettay

13

1 reference

Europe PubMed Central

26 July 2017

Raymond R Tubbs

14

1 reference

Europe PubMed Central

26 July 2017

Thomas M Grogan

15

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 October 2008

1 reference

Europe PubMed Central

26 July 2017

Diagnostic Pathology

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

41

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1186/1746-1596-3-41

0 references

Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Metallographic in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Analysis of HER2 gene amplification using an automated fluorescence in situ hybridization signal enumeration system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

HER2 testing in the UK: consensus from a national consultation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Novel bright field molecular morphology methods for detection of HER2 gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

21 June 2018

111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Standardization of HER2 testing: results of an international proficiency-testing ring study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577627

31 October 2018

Standardizing Slide-Based Assays in Breast Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel triple-color detection procedure for brightfield microscopy, combining in situ hybridization with immunocytochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-colour brightfield in situ hybridisation on tissue sections

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inconsistency of HER2 test raises questions

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18945356

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1746-1596-3-41

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33378811&oldid=1967262200"